Zevra Q1 2026 net revenue $36.2M (+78% YoY); net income $37.9M; cash $236.8M after debt repayment

ZEVRA THERAPEUTICS, INC.

2026-Q1 EPS reported $0.60 revenue$36,220,000

MIPLYFFA net revenue $24.6M; total net revenue $36.2M vs $20.4M in Q1 2025.
Completed $50M sale of SDX portfolio to Commave Therapeutics; prepaid $63.1M term loan, now debt-free.
Net income of $37.9M ($0.60 diluted) includes $43.3M one-time gain; adjusted net income $11.5M ($0.18 diluted).
Cash, equivalents and securities $236.8M as of March 31, 2026; no near-term capital market dependency.
Enrolled 62 patients in Phase 3 DiSCOVER trial for Vascular Ehlers-Danlos Syndrome; FDA meeting expected H2 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ZEVRA THERAPEUTICS, INC. reported the first quarter ended March 31, 2026 results: revenue $36.2 million, net income $37.9 million, EPS $0.62 per basic and $0.60 diluted share.

Period: the first quarter ended March 31, 2026
Revenue: $36.2 million
Net income: $37.9 million
EPS: $0.62 per basic and $0.60 diluted share
Result: reported results

Exact text from the filing

set forth by specific reference in any such filing. --- EX-99.1 (EX-99.1) --- Zevra Reports First Quarter 2026 Financial Results and Corporate Update Q1 2026 net revenue of $36.2 million, a 78% increase over Q1 2025 Completed $50.0 million sale of SDX portfolio to Commave Therapeutics Operational execution fueled strong cash position of $236.8 million Company to

View on SEC.gov

Browse all earnings releases →

ZEVRA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001434647-26-000029

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.